10x Genomics (NASDAQ: TXG) insider plans sale of 17,948 shares

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) received a Rule 144 notice relating to proposed sales of its common stock by Serge Saxonov. The notice covers up to 17,948 shares of common stock, with an indicated aggregate market value of $1,168,773.76, to be sold through Morgan Stanley Smith Barney LLC on or after August 24, 2026. The filing states that 10x Genomics had 120,212,296 shares of common stock outstanding. The securities to be sold were acquired via a Restricted Stock Unit Grant of 35,271 shares from the issuer in exchange for services rendered, with acquisition dated August 21, 2026.

The notice also lists prior sales of 10x Genomics common stock by Serge Saxonov during the past three months, including transactions on May 26, 2026 and June 22, 2026 at stated share counts and dollar amounts.

Key Figures

Shares proposed to be sold: 17,948 shares Aggregate market value of shares proposed to be sold: $1,168,773.76 Shares outstanding: 120,212,296 shares +3 more

6 metrics

Shares proposed to be sold 17,948 shares Common stock under Rule 144 notice for Serge Saxonov

Aggregate market value of shares proposed to be sold $1,168,773.76 Value of 17,948 TXG shares covered by the notice

Shares outstanding 120,212,296 shares 10x Genomics common stock outstanding as stated in the notice

Shares acquired via Restricted Stock Unit Grant 35,271 shares Common stock granted to Serge Saxonov from issuer for services rendered

Past sale on May 26, 2026 10,718 shares for $264,833.21 Sale of 10x Genomics common stock by Serge Saxonov

Past sale on June 22, 2026 (example) 9,991 shares for $342,506.47 One of several sales of TXG common stock on June 22, 2026

Key Terms

Rule 144, Restricted Stock Unit Grant, services rendered

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Unit Grant financial

"Common Stock | 08/21/2026 | Restricted Stock Unit Grant | Issuer"

services rendered financial

"35271 | 08/24/2026 | Services Rendered"

FAQ

What does the Form 144 filing for TXG disclose about Serge Saxonov’s planned stock sales?

The Form 144 notice discloses a proposed sale of up to 17,948 shares of 10x Genomics (TXG) common stock by Serge Saxonov, with an indicated aggregate market value of $1,168,773.76, through Morgan Stanley Smith Barney LLC on or after August 24, 2026.

How many TXG shares are outstanding according to this Form 144?

The notice states that 10x Genomics (TXG) had 120,212,296 shares of common stock outstanding. This figure provides context for the size of the proposed sale under Rule 144 relative to the company’s total common shares.

How were the TXG shares covered by this Form 144 acquired by Serge Saxonov?

The securities to be sold were acquired via a Restricted Stock Unit Grant of 35,271 shares of 10x Genomics common stock from the issuer, dated August 21, 2026, in exchange for services rendered.

Which broker is named in the TXG Form 144 filing for Serge Saxonov?

The notice identifies Morgan Stanley Smith Barney LLC Executive Services as the broker for the proposed sale of 10x Genomics (TXG) common stock, with the transactions expected on or after August 24, 2026.

What prior TXG stock sales by Serge Saxonov are listed in the past 3 months?

The notice lists 10x Genomics (TXG) common stock sales by Serge Saxonov on May 26, 2026 (10,718 shares for $264,833.21) and multiple sales on June 22, 2026, including transactions of 8,527, 9,991, 9,821, and 1,661 shares with stated dollar amounts.

What is the nature of consideration for the TXG shares acquired by Serge Saxonov?

The filing states that the 35,271 10x Genomics (TXG) common shares covered in the acquisition section were received via a Restricted Stock Unit Grant from the issuer for services rendered, with a payment date of August 24, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 06:25 PM Accepted by SEC EDGAR 08/24/2026 - 06:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001786720
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	10x Genomics, Inc.
SEC File Number	001-39035
Address of Issuer	6230 STONERIDGE MALL ROAD PLEASANTON CALIFORNIA 94588
Phone	(925) 401-7300
Name of Person for Whose Account the Securities are To Be Sold	Saxonov Serge
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Services 200 W Civic Center Dr., 4th Floor Sandy UT 84070	17948	1168773.76	120212296	08/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/21/2026	Restricted Stock Unit Grant	Issuer			35271	08/24/2026	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Serge Saxonov 6230 Stoneridge Mall Road Pleasanton CA 94588	Common Stock	05/26/2026	10718	264833.21
Serge Saxonov 6230 Stoneridge Mall Road Pleasanton CA 94588	Common Stock	06/22/2026	8527	283855.30
Serge Saxonov 6230 Stoneridge Mall Road Pleasanton CA 94588	Common Stock	06/22/2026	9991	342506.47
Serge Saxonov 6230 Stoneridge Mall Road Pleasanton CA 94588	Common Stock	06/22/2026	9821	346837.45
Serge Saxonov 6230 Stoneridge Mall Road Pleasanton CA 94588	Common Stock	06/22/2026	1661	60069.40

144: Remarks and Signature

Remarks
Date of Notice	08/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Randy Wu, as Attorney-in-Fact for Serge Saxonov
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)